Table 1.
Baseline sociodemographic and clinical characteristics of participants in the extended monitoring group compared with the control group
| Baseline characteristics | Extended monitoring group (n = 459) | Control group (n = 110) |
|---|---|---|
| Male gender, n (%) | 308 (67) | 73 (66) |
| Age, years: mean (s.d.) | 49 (12) | 48 (10) |
| Duration of illness, years: mean (s.d.) | 19 (6) | 25 (16) |
| Clozapine dose, mg: mean (s.d.) | 356 (146) | 366 (153) |
| BEN diagnosis, n (%) | 29 (6) | 0 (0) |
| Time to clozapine initiation from illness onset, years | ||
| Mean (s.d.) | 8 (7) | 8 (6) |
| Median (IQR) | 5 (3–12) | 7 (2–12) |
| Duration of clozapine treatment, years | ||
| Mean (s.d.) | 11 (6) | 14 (7) |
| Median (IQR) | 13 (6–17) | 16 (11–19) |
| ICD-10 diagnosis, n (%) | ||
| F20 Paranoid schizophrenia | 354 (77) | 102 (93) |
| F25 Schizoaffective disorder | 59 (13) | 4 (3) |
| F31 Bipolar disorder | 12 (3) | 0 (0) |
| Other | 34 (8) | 4 (0) |
| Psychiatric comorbidity, n (%) | 48 (10) | 16 (15) |
| Ethnicity, n (%) | ||
| White | 193 (42) | 57 (52) |
| Black | 164 (36) | 37 (34) |
| Asian | 40 (9) | 10 (9) |
| Other | 62 (13) | 6 (5) |
| Concomitant psychotropic medication, n (%) | ||
| Antipsychotic | 126 (27) | 34 (31) |
| Mood stabilisera | 146 (32) | 23 (21) |
| Antidepressant | 135 (29) | 26 (24) |
BEN, benign ethnic neutropenia; IQR, interquartile range.
a.
Lithium, valproate or lamotrigine.